1-1 of 1
Philip Dy, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD ® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group

Andrew M Evens, DO,MSc, Fangxin Hong, PhD, Thomas M Habermann, MD, Ranjana H. Advani, MD, Randy D. Gascoyne, MD, Thomas E Witzig, MD, Andrew Quon, MD, Erik A. Ranheim, MD PhD, Puneet Cheema, MD, Philip Dy, MD, Timothy E. O'Brien, MD, Jane N. Winter, MD, Terrence Paul Cescon, Julie Chang, MD, Brad S Kahl, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 482.
https://doi.org/10.1182/blood.V130.Suppl_1.482.482
Published: 2017